CDT Equity (NASDAQ:CDT) Issues Quarterly Earnings Results

CDT Equity (NASDAQ:CDT) posted its quarterly earnings results on Wednesday. The company reported ($8.71) EPS for the quarter, Zacks reports.

CDT Equity Price Performance

NASDAQ CDT traded down $0.03 during trading on Wednesday, reaching $2.93. 18,708 shares of the company’s stock traded hands, compared to its average volume of 299,725. The firm has a market cap of $1.85 million, a price-to-earnings ratio of -0.00 and a beta of 1.52. The company’s 50 day simple moving average is $5.43 and its two-hundred day simple moving average is $78.79. CDT Equity has a 12-month low of $2.53 and a 12-month high of $3,700.00.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Wall Street Zen upgraded shares of CDT Equity from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CDT Equity in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

CDT Equity Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.